The major differences between the present post hoc FEATHER study and the CKD-FIX study were the CKD stage (stage 3 vs. stages 3–4), eGFR (45.2 vs. 31.7 mL/min/1.73 m2), eGFR slope in the placebo group (− 0.31 vs. − 3.33 mL/min/1.73 m2/year), urinary albumin-to-creatinine ratio (117.0 vs. 716.9 mg/g), proportion of patients with diabetes (29% vs. 45%), ethnicity of the participants (100% Asian vs. 5% Asian), and the agent used (febuxostat vs. allopurinol). This evidence concerns the gene ALB and chronic kidney disease.